Abstract 17499: ETC-1002 Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia Receiving Stable Statin Therapy

Background: ETC-1002 is an oral investigational drug that modulates hepatic adenosine triphosphate-citrate lyase to reduce cholesterol biosynthesis and may be beneficial in treating patients with elevated LDL-C despite using stable statin therapy. Methods: A double-blind, parallel group, placebo-controlled multicenter trial evaluated patients (n=134) with baseline LDL-C of 115-220 mg/dL while taking atorvastatin ≤20 mg, simvastatin ≤20 mg, rosuvastatin ≤10mg or pravastatin ≤40 mg randomized to ETC-1002 120 mg, ETC-1002 180 mg, or placebo once daily for 12 weeks. Results: ETC-1002 120 mg (p=0.0055) and 180 mg (pu003c0.0001) lowered LDL-C significantly more than placebo (primary endpoint) as an add-on to statin therapy. ETC-1002 also lowered (pu003c0.05) apolipoprotein B, non-high density lipoprotein-cholesterol, total cholesterol and LDL particle number more than placebo. C-reactive protein was also reduced with ETC-1002 120 mg (22%, p=0.26) and 180 mg (30%, p=0.08) versus 0% with placebo. Adverse events (AEs), mu...